Towards Healthcare Research & Consulting

Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Companies and Competitive Landscape

Date : 12 June 2026

Who are the Top Companies and What are Their Offerings?

Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Companies are AstraZeneca plc, Alnylam Pharmaceuticals, Inc., Chugai Pharmaceuticals, Akari Therapeutics Plc, Novartis AG, BioCryst Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, Regeneron Pharmaceuticals, Inc.

Recent Developments in the Market

  • In April 2026, at the 2026 World Congress of Nephrology meeting, held in Yokohama, Japan, the findings of phase 3 COMMODORE 1 and 2 clinical trials were announced. The finding reported that crovalimab may offer stable improvement in the fatigue levels of paroxysmal nocturnal hemoglobinuria (PNH) patients.
  • In October 2025, PiaSky, a drug for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) developed by Chugai Pharmaceutical Co., Ltd., was launched by Chugai Pharma Taiwan Ltd. (CPT). The drug is the first subcutaneous treatment approved in Taiwan for patients aged 13 years and older with at least 40 kg of body weight.

Market Ecosystem Analysis

Ecosystem Segment Key Participants Role in Market
Technology Providers AstraZeneca/Alexion, Roche, Novartis, Apellis Development of complement pathway therapies
Product Manufacturers AstraZeneca, Roche, Novartis, Apellis, Sanofi Manufacturing biologics and targeted therapies
Service Providers Specialty infusion centers, hospital networks Drug administration and patient monitoring
Platform Providers Complement biology and monoclonal antibody technology firms Enable next-generation therapeutic development
CROs IQVIA, ICON, Syneos Health, Parexel Clinical trial management and regulatory support
CDMOs Lonza, Samsung Biologics, Fujifilm Diosynth Biol

Market Value Chain Analysis

R&D

  • The R&D of the Japan paroxysmal nocturnal hemoglobinuria treatment focuses on mitigating residual extravascular hemolysis, expanding oral or long-acting subcutaneous delivery methods, and overcoming domestic C5 genetic mutations.
  • Key players: AstraZeneca plc, Novartis AG, and Chugai Pharmaceuticals.

Clinical Trials and Regulatory Approvals

  • The therapeutic safety, efficacy, long-term stabilization of hemoglobin levels, and prevention of intravascular and extravascular hemolysis are evaluated in the clinical trials and regulatory approvals of the paroxysmal nocturnal hemoglobinuria treatment in Japan.
  • Key players: AstraZeneca plc, Novartis AG, and Chugai Pharmaceuticals.

Formulation and Final Dosage Preparation

  • The formulation and final dosage preparation of the paroxysmal nocturnal hemoglobinuria treatment in Japan involves the development of high-concentration subcutaneous solutions, immediate-release oral tablets, and lyophilised powders.
  • Key players: AstraZeneca plc, Novartis AG, and Chugai Pharmaceuticals.

Packaging and Serialization

  • The packaging and serialization of paroxysmal nocturnal hemoglobinuria treatment in Japan involve the use of temperature-insulated cold chain boxes with GS-1-compliant data matrix barcodes for real-time traceability.
  • Key players: AstraZeneca plc, Novartis AG, and Chugai Pharmaceuticals.

Distribution to Hospitals, Pharmacies

  • The specialized cold chain orphan drug networks and strictly monitored medical procurement channels are responsible for the distribution of paroxysmal nocturnal hemoglobinuria treatments to the hospitals and pharmacies in Japan.
  • Key players: AstraZeneca plc, Novartis AG, and Chugai Pharmaceuticals.

Patient Support and Services

  • The subsidized copayment navigation under the Intractable Diseases Healthcare Act, disease education kits, personalized home nursing coordination, and 24/7 adverse event hotlines are provided in the patient support and services of the paroxysmal nocturnal hemoglobinuria treatment in Japan.
  • Key players: AstraZeneca plc, Novartis AG, and Chugai Pharmaceuticals.
Tier 1
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to PNH
AstraZeneca Cambridge, England UK Market leader through Alexion franchise; established standard of care Soliris (eculizumab), Ultomiris (ravulizumab), Voydeya (danicopan)
Novartis Basel Switzerland First oral monotherapy approved in Japan Fabhalta (iptacopan) (Grand View Research)
Roche Basel Switzerland Developer of crovalimab/PiaSky PiaSky (crovalimab) (Chugai Pharmaceutical)
Apellis Pharmaceuticals Waltham, Massachusetts USA Leading C3 inhibition innovator Empaveli (pegcetacoplan) (Grand View Research)
Sanofi Paris France Expanding rare disease portfolio and complement pathway investments Rare disease biologics and immunology portfolio
Tier 2
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to PNH
Chugai Pharmaceutical Tokyo Japan Commercializes PiaSky in Japan PiaSky (crovalimab) (Chugai Pharmaceutical)
BioCryst Pharmaceuticals Durham, North Carolina USA Developing complement pathway assets Oral complement-targeted pipeline (Grand View Research)
Amgen Thousand Oaks, California USA Biosimilar and complement-related hematology presence Bkemv (eculizumab biosimilar) (Reuters)
Regeneron Pharmaceuticals Tarrytown, New York USA Complement and immunology research programs Complement-targeted pipeline assets
Johnson & Johnson New Brunswick, New Jersey USA Emerging rare hematology investments Rare disease and hematology pipeline (Grand View Research)
Tier 3
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to PNH
Pfizer New York, New York USA Active in rare disease development and hematology Rare disease biologics pipeline
Sobi Stockholm Sweden Commercialization partner for Empaveli in several markets including Japan collaboration activities PNH commercialization support (Grand View Research)
Omeros Corporation Seattle, Washington USA Complement pathway inhibitor development MASP-2 inhibitor programs
Annexon Biosciences Brisbane, California USA Complement biology specialist Classical complement inhibition platform
Akari Therapeutics Boston, Massachusetts USA Focused complement-mediated disease therapies Complement inhibitor pipeline

Market Growth

The Japan paroxysmal nocturnal hemoglobinuria treatment market size was valued at US$ 279.95 million in 2025 and is projected to grow to 296.41 million in 2026. Forecasts suggest it will reach approximately US$ 495.7 million by 2035, registering a CAGR of 5.88% during the period.

Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size is USD 296.41 Million in 2026.